CAR-T Meeting 2020 | The patient’s voice in CAR T-cell regulatory processes
Bregje Verhoeven
• 30 Jan 2020
Bregje Verhoeven, European Society for Blood & Marrow Transplantation (EBMT), Leiden, The Netherlands, outlines the importance of incorporating the patient’s voice in the regulatory processes of CAR T-cell therapy. Ms Verhoeven discusses the value of patient-reported outcomes as they can describe the quality of life and how it should be incorporated in the health technology assessments (HTAs). This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
